为您找到"
FNIH-055
"相关结果约100,000,000个
Connecting world-leading NIH researchers with the ingenuity and expertise of biopharma, academia, and non-profit partners
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) PAR-25-055.
The Validation & Qualification Network is a new public-private partnership that would accelerate the implementation New Approach Methodologies.
The Biomarkers Consortium is a pre-competitive public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop, and seek regulatory acceptance of drug development tools/solutions (e.g. disease biomarkers and surrogate endpoints) to support new drug ...
Our Programs We seek to solve complex health challenges and accelerate medical breakthroughs for patients, regardless of who they are, where they live or what disease they have.
About the FNIH Biomarkers Consortium Established by Congress in 1990 to support the mission of the National Institutes of Health (NIH), the Foundation for the NIH (FNIH) builds public-private partnerships that connect leading biomedical scientists at the NIH, life sciences companies, foundations, academia, and regulatory agencies.
While this cohort and the FNIH Biomarkers Consortium project was designed to evaluate the longitudinal trajectories of AD blood biomarkers in relation to amyloid PET, the current study was a cross‐sectional head‐to‐head comparison of leading commercially available blood tests.
The use of digital health products has gained considerable interest as a new way to improve therapeutic research and development. Although these products are being adopted by various industries and stakeholders, their incorporation in clinical trials has been slow due to a disconnect between the promises of digital products and potential risks in using these new technologies in the absence of ...
Cost-effectiveness of intrapartum azithromycin to prevent maternal infection, sepsis, or death in low-income and middle-income countries The Lancet Global Health
The Foundation for the National Institutes of Health (FNIH) sample was selected for a nested case-control study designed to evaluate the predictive validity of a broad spectrum of imaging and biochemical markers of disease progression in knee OA derived from the Osteoarthritis Initiative (OAI) public data base, an ongoing multi-center ...